... including integrin-linked kinase (ILK) and mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2) can also ... A mosaic-activating mutation (c. 49G→A, p.Glu17Lys) in Akt1 is associated with the Proteus Syndrome, which causes overgrowth of ... Akt inhibitors may treat cancers such as neuroblastoma. Some Akt inhibitors have undergone clinical trials. In 2007 VQD-002 had ... For example, PI 3-kinases may be activated by a G protein coupled receptor or receptor tyrosine kinase such as the insulin ...

"Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells". Molecular ... This drug is a Farnesyltransferase inhibitor which inhibits the Ras kinase in a post translational modification step before the ... Malignant peripheral nerve sheath tumor Neurofibromatosis Neurofibromin Genetic disorder Watson syndrome Proteus syndrome ... The functional part of neurofibromin is a GAP, or GTPase-activating protein. GAP accelerates the conversion of the active GTP- ...

Many phakomatoses are caused by mutations which alter functioning of the RAS-mitogen-activated protein kinase (MAPK) pathway ... A major development in the treatment of this condition occurred in 2010s when the FDA approved mTOR inhibitors for the ... Some neurocutaneous disorders are found exclusively as mosaics such as Sturge-Weber syndrome and Proteus syndrome. Others such ... Sturge-Weber syndrome occurs in approximately 1 in 20,000-50,000 live births and is caused by a somatic activating mutation in ...